Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NIH revamp rushes ahead

Nature volume 471, pages 15–16 (2011)Cite this article

Subjects

Translational-science centre remains on the fast track, despite concerns about upheaval.

Jeremy Berg was fighting rush-hour traffic on his way home from the US National Institutes of Health (NIH) in Bethesda, Maryland, on 8 February when he took an unexpected call. On the line was a senior NIH official who was helping to plan the dismantling of the agency's National Center for Research Resources (NCRR) to make way for a translational-medicine centre strongly backed by Francis Collins, director of the NIH.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Meredith Wadman
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related external links

NCRR Task Force on NCRR dissolution

NIH feedback blog on NCATS

NIH Scientific Management Review Board

SMRB Working Group on Translational Medicine and Therapuetics

National Center for Research Resources

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wadman, M. NIH revamp rushes ahead. Nature 471, 15–16 (2011). https://doi.org/10.1038/471015a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/471015a

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research